IHE iShares U.S. Pharmaceuticals ETF
Quote as of Aug 26, 2026 20:00 UTC · Market data delayed approximately 15–20 minutes unless otherwise indicated.
| Previous Close | 107.41 | Day Range | 105.89 – 107.24 |
| 52-Week Range | 69.02 – 108.66 | Volume | 96.75K |
| Avg Volume | 197.56K | AUM | $1.77B (Aug 26, 2026) |
| Expense Ratio | 0.37% | Yield (TTM) | 1.37% |
| NAV | 107.44 | Premium/Discount | -1.41% indicative |
| Inception | May 01, 2006 | Holdings | 56 |
| Issuer | iShares | Exchange | AMEX |
| Category | Healthcare | Index Tracked | Not stated in source data |
| CUSIP | 464288836 | ISIN | US4642888360 |
| Management | Not stated in source data | ||
About this ETF
The iShares U.S. Pharmaceuticals ETF is designed to replicate the investment performance of a benchmark index. This index consists solely of equity securities from pharmaceutical companies operating within the United States.
Description from the fund data provider · profile as of Aug 26, 2026.
Price Chart
Daily closing prices (price return, not total return). Comparison lines are normalized to percent change from the range start. Source: Financial Modeling Prep.
Performance
| 1M | 3M | 6M | YTD | 1Y | 3Y* | 5Y* | 10Y* | Incep.* | |
|---|---|---|---|---|---|---|---|---|---|
| Price return | +4.91% | +17.79% | +17.26% | +26.62% | +53.36% | +19.27% | +10.74% | +7.96% | +9.58% |
| Total return | +4.91% | +18.14% | +17.99% | +27.41% | +56.07% | +21.28% | +12.66% | +9.61% | +11.19% |
* Annualized. Total return uses the dividend-adjusted price series (distributions reinvested); price return uses unadjusted closes. Performance through Aug 25, 2026. Past performance does not guarantee future results.
Fees
| Net expense ratio | 0.37% | Annual cost of a $10,000 investment | $37.00 |
Illustrative calculation only: expense ratio × $10,000. It excludes trading costs, bid/ask spreads, taxes and changes in investment value. Gross vs. net expense details and any fee waivers are in the prospectus.
Holdings
Holdings as of Aug 25, 2026 — portfolio reporting date from the data provider; holdings are not live positions. 59 rows in database.
| # | Holding | Ticker | Weight | Shares | Market Value |
|---|---|---|---|---|---|
| 1 | JOHNSON & JOHNSON | JNJ | 22.36% | 1.44M | $392.7M |
| 2 | ELI LILLY | LLY | 21.43% | 301.82K | $376.3M |
| 3 | MERCK & CO INC | MRK | 4.94% | 576.00K | $86.8M |
| 4 | BRISTOL MYERS SQUIBB | BMY | 4.73% | 1.23M | $83.0M |
| 5 | ROYALTY PHARMA PLC CLASS A | RPRX | 4.39% | 1.26M | $77.2M |
| 6 | PFIZER | PFE | 4.27% | 2.68M | $74.9M |
| 7 | VIATRIS | VTRS | 4.07% | 4.33M | $71.5M |
| 8 | ZOETIS INC CLASS A | ZTS | 3.71% | 843.84K | $65.1M |
| 9 | JAZZ PHARMACEUTICALS PLC | JAZZ | 3.38% | 233.05K | $59.3M |
| 10 | ELANCO ANIMAL HEALTH | ELAN | 2.58% | 1.86M | $45.3M |
| 11 | CORCEPT THERAPEUTICS | CORT | 2.49% | 354.89K | $43.7M |
| 12 | CRINETICS PHARMACEUTICALS | CRNX | 1.89% | 391.65K | $33.2M |
| 13 | AXSOME THERAPEUTICS | AXSM | 1.88% | 160.56K | $33.0M |
| 14 | LIGAND PHARMACEUTICALS | LGND | 1.19% | 74.44K | $20.9M |
| 15 | DEFINIUM THERAPEUTICS INC | DFTX | 1.19% | 481.60K | $20.8M |
| 16 | LIQUIDIA | LQDA | 1.04% | 260.90K | $18.3M |
| 17 | INDIVIOR PHARMACEUTICALS INC | INDV | 0.93% | 452.87K | $16.4M |
| 18 | AMYLYX PHARMACEUTICALS | AMLX | 0.80% | 367.44K | $14.0M |
| 19 | ORGANON | OGN | 0.76% | 975.41K | $13.4M |
| 20 | EDGEWISE THERAPEUTICS | EWTX | 0.71% | 279.75K | $12.5M |
| 21 | ENLIVEN THERAPEUTICS | ELVN | 0.70% | 202.34K | $12.4M |
| 22 | AMNEAL PHARMACEUTICALS CLASS A | AMRX | 0.65% | 639.89K | $11.4M |
| 23 | TARSUS PHARMACEUTICALS | TARS | 0.61% | 147.03K | $10.7M |
| 24 | SUPERNUS PHARMACEUTICALS | SUPN | 0.55% | 215.54K | $9.7M |
| 25 | NEKTAR THERAPEUTICS | NKTR | 0.53% | 125.46K | $9.2M |
Click a ticker to see every ETF that owns it.
Sector Exposure
Geographic Exposure
Country weights as reported by the data provider. Developed/emerging/frontier labels follow the classification on the Methodology page. Currency hedged: No hedging indicated in the fund name.
Distributions
| Yield (TTM) | 1.37% | Paid (last 12 months) | $1.4669 |
| Frequency | Quarterly | SEC yield | Not provided by our data source — see the issuer page |
| Last ex-date | Jun 15, 2026 | Last payment | $0.2848 (Jun 18, 2026) |
| Growth 1Y | +25.60% | Growth 3Y / 5Y (ann.) | -25.05% / -10.75% |
| Ex-date | Record | Pay date | Amount |
|---|---|---|---|
| Jun 15, 2026 | Jun 15, 2026 | Jun 18, 2026 | $0.2848 |
| Mar 17, 2026 | Mar 17, 2026 | Mar 20, 2026 | $0.2845 |
| Dec 16, 2025 | Dec 16, 2025 | Dec 19, 2025 | $0.5853 |
| Sep 16, 2025 | Sep 16, 2025 | Sep 19, 2025 | $0.3124 |
| Jun 16, 2025 | Jun 16, 2025 | Jun 20, 2025 | $0.3065 |
| Mar 18, 2025 | Mar 18, 2025 | Mar 21, 2025 | $0.2917 |
| Dec 17, 2024 | Dec 17, 2024 | Dec 20, 2024 | $0.2108 |
| Sep 25, 2024 | Sep 25, 2024 | Sep 30, 2024 | $0.3589 |
| Jun 11, 2024 | Jun 11, 2024 | Jun 17, 2024 | $0.2940 |
| Mar 21, 2024 | Mar 22, 2024 | Mar 27, 2024 | $0.2750 |
| Dec 20, 2023 | Dec 21, 2023 | Dec 27, 2023 | $0.4042 |
| Sep 26, 2023 | Sep 27, 2023 | Oct 02, 2023 | $0.9018 |
Trailing distribution yield = last 12 months of cash ÷ current price. It is NOT the SEC 30-day yield and distributions are not guaranteed to continue. The difference explained →
Risk Statistics
| Volatility 1Y / 3Y | 17.96% / 17.04% | Sharpe 1Y / 3Y | 3.07 / 1.14 |
| Max drawdown 1Y / 3Y | -8.47% / -15.92% | Sortino 1Y | 5.43 |
| Beta vs S&P 500 (3Y) | 0.49 | Correlation vs S&P 500 (1Y) | 0.247 |
| Downside deviation 1Y | 10.15% | Risk-free rate used | 3.72% (3M T-bill, FRED) |
Computed by ETF Explorer from daily dividend-adjusted closes; volatility and drawdown are annualized/period figures; S&P 500 exposure proxied by SPY. As of Aug 26, 2026. Formulas →
Liquidity
| Volume today | 96.75K | Average volume | 197.56K |
| AUM | $1.77B | Premium/Discount | -1.41% |
| Bid/Ask spread | Not provided by our data source. Check your broker's quote screen; spreads are widest at the open and close. | ||
Premium/discount compares the delayed market price with the last reported NAV — an indicative figure, not the official closing premium/discount. How ETF liquidity works →
Fund Flows (estimated)
| Period | Est. net flow | % of starting AUM | AUM start → end |
|---|---|---|---|
| 1 Day | $22.1M | +1.27% | $1.75B → $1.77B |
| 1 Week | $90.2M | +5.34% | $1.69B → $1.77B |
ETF Explorer estimate: change in reported AUM minus the market-move effect, from our own daily snapshots. Not official issuer creation/redemption data.
Official Fund Resources
External links open the issuer's site or SEC EDGAR in a new tab. The prospectus and official documents are always the authoritative source — review them before investing.
Latest News for IHE
No articles mention this fund directly in the last 7 days — showing general ETF coverage.
Guided help: AUM is fund size. The expense ratio is the yearly cost baked into returns. NAV is the value of what the fund owns per share; the market price can sit slightly above (premium) or below (discount) it. Total return assumes distributions were reinvested. Every dataset shows its own as-of date because holdings, assets and quotes update on different schedules.